XPD Asp312Asn polymorphism is a risk factor for prostate cancer
Shao-Guang Liao1, Lu Liu, Ying Wang
1Department of Oncology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai 200433, People's Republic of China. liaosg1982@gmail.com
The Xeroderma pigmentosum Group D (XPD) Asp312Asn polymorphism increases prostate cancer risk, particularly in Asian populations. The Lys751Gln polymorphism showed no significant association with prostate cancer risk.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Genetic variations, specifically polymorphisms, are increasingly recognized for their role in disease susceptibility.
- The Xeroderma pigmentosum Group D (XPD) gene is involved in DNA repair, making its polymorphisms potential factors in cancer development.
- Previous studies on the association between XPD polymorphisms (Asp312Asn and Lys751Gln) and prostate cancer risk have yielded inconclusive results.
Purpose of the Study:
- To conduct a meta-analysis to clarify the association between XPD Asp312Asn and Lys751Gln polymorphisms and prostate cancer risk.
- To provide a more robust understanding of the genetic contribution of these XPD polymorphisms to prostate cancer development.
Main Methods:
- An extensive literature search was performed to identify relevant case-control studies.
- Studies investigating the association between XPD Asp312Asn and Lys751Gln polymorphisms and prostate cancer were included.
- Statistical analysis using odds ratios (OR) and 95% confidence intervals (95% CI) was employed to assess the strength of association.
Main Results:
- Seven case-control studies were included in the meta-analysis.
- The Asp312Asn polymorphism was significantly associated with an increased risk of prostate cancer in additive and recessive genetic models (P=0.00 for both).
- Subgroup analysis revealed that the Asp312Asn polymorphism was associated with increased prostate cancer risk among Asians across all genetic models.
- No significant association was found between the Lys751Gln polymorphism and prostate cancer risk in overall or subgroup analyses.
Conclusions:
- The XPD Asp312Asn polymorphism is identified as a risk factor for prostate cancer development.
- The findings highlight the importance of the Asp312Asn polymorphism, especially in Asian populations, for prostate cancer risk.
- Further research may be warranted to explore the underlying mechanisms and clinical implications.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Abnormal Proliferation
Pleiotropy
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
